Elidel and Injection site urticaria - a phase IV clinical study of FDA data

Summary:

Injection site urticaria is reported as a side effect among people who take Elidel (pimecrolimus), especially for people who are male, 10-19 old, also take Singulair, and have Asthma.

The phase IV clinical study analyzes which people have Injection site urticaria when taking Elidel. It is created by eHealthMe based on reports of 5,143 people who have side effects when taking Elidel from the FDA, and is updated regularly.

What is Elidel?

Elidel has active ingredients of pimecrolimus. It is often used in eczema. eHealthMe is studying from 5,201 Elidel users. Check the latest studies of Elidel.

What is Injection site urticaria?

Injection site urticaria (rash of round, red welts on the skin at injection site) is found to be associated with 557 drugs and 612 conditions by eHealthMe. Check the latest studies of Injection site urticaria.

On Jul, 11, 2026

5,143 people reported to have side effects when taking Elidel.
Among them, 11 people (0.21%) have Injection site urticaria.

Could Elidel cause Injection site urticaria?

Among these 11 people:

What is the gender of people who have Injection site urticaria when taking Elidel? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Injection site urticaria when taking Elidel? *

What are other drugs people take besides Elidel? *

What are other side effects people have besides Injection site urticaria? *

Generalised Oedema (swelling all over the body): 6 people, 54.55%
Thyroid Diseases: 5 people, 45.45%
Cough: 5 people, 45.45%
Rhinorrhea (watery mucus discharge from the nose): 5 people, 45.45%
Headache (pain in head): 5 people, 45.45%
Hypotension (abnormally low blood pressure): 5 people, 45.45%
Asthma: 4 people, 36.36%
Malaise (a feeling of general discomfort or uneasiness): 4 people, 36.36%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 18.18%
Injection Site Erythema (redness at injection site): 2 people, 18.18%

What are the existing conditions these people have? *

Asthma: 8 people, 72.73%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 27.27%
Stress And Anxiety: 1 person, 9.09%
Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 1 person, 9.09%
Depression: 1 person, 9.09%
Fungal Skin Infection: 1 person, 9.09%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 9.09%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 9.09%
High Blood Pressure: 1 person, 9.09%
Vitamin B1 Deficiency: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Elidel and have Injection site urticaria?

- Check whether Injection site urticaria is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Elidel:

Elidel (5,201 reports)

Browse all side effects of Elidel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site urticaria:

Injection site urticaria (557 drugs)

Browse all the conditions that are associated with Injection site urticaria:

Injection site urticaria (612 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pimecrolimus (the active ingredients of Elidel) and Elidel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.